Search Results - Nadège Gaborit

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3

    Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3 by Nadège Gaborit, Moshit Lindzen, Yosef Yarden

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption

    In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptor... by Christel Larbouret, Nadège Gaborit, Thierry Chardès, Mickaël Coelho, Emmanuelle Campigna, Caroline Mollévi, Jean‐Pierre Mach, D. Azria, Bruno Robert, André Pèlegrin

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR

    Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR by Daniela A. Ferraro, Nadège Gaborit, Ruth Maron, Hadas Cohen‐Dvashi, Ziv Porat, Fresia Pareja, Sara Lavi, Moshit Lindzen, Nir Ben‐Chetrit, Michael Sela, Yosef Yarden

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers

    Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers by Nadège Gaborit, Christel Larbouret, Julie Vallaghe, Frédéric Peyrusson, Caroline Mollévi, Evelyne Lopez‐Crapez, D. Azria, Thierry Chardès, Marie‐Alix Poul, Gérard Mathis, Hervé Bazin, André Pèlegrin

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Examination of HER3 targeting in cancer using monoclonal antibodies

    Examination of HER3 targeting in cancer using monoclonal antibodies by Nadège Gaborit, Ali Abdul‐Hai, Maicol Mancini, Moshit Lindzen, Sara Lavi, Orith Leitner, Lucile Mounier, Myriam Chentouf, Sai Dunoyer, Manjusha Ghosh, Christel Larbouret, Thierry Chardès, Hervé Bazin, André Pèlegrin, Michael Sela, Yosef Yarden

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer

    An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer by Laura Bourillon, C. Bourgier, Nadège Gaborit, Véronique Garambois, Eva Llès, Alexandre Zampieri, Charline Ogier, Marta Jarlier, Nina Radosevic‐Robin, Béatrice Orsetti, Hélène Delpech, Charles Theillet, Pierre‐Emmanuel Colombo, D. Azria, André Pèlegrin, Christel Larbouret, Thierry Chardès

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

    HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models by Gaëlle Thomas, Thierry Chardès, Nadège Gaborit, Caroline Mollévi, Wilhem Leconet, Bruno Robert, Nina Radosevic‐Robin, Frédérique Penault‐Llorca, Céline Gongora, Pierre‐Emmanuel Colombo, Yassamine Lazrek, Rui Bras-Gonçalves, Ariel Savina, D. Azria, Hervé Bazin, André Pèlegrin, Christel Larbouret

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer

    Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cance... by Charline Ogier, Pierre‐Emmanuel Colombo, Corinne Bousquet, Lucile Canterel-Thouennon, Pierre Sicard, Véronique Garambois, Gaëlle Thomas, Nadège Gaborit, Marta Jarlier, Nelly Pirot, Martine Pugnière, Nadia Vié, Céline Gongora, Pierre Martineau, Bruno Robert, André Pèlegrin, Thierry Chardès, Christel Larbouret

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

    Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor by Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-García, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Kittel, Nadège Gaborit, Gretchen Bergado Báez, Belinda Sánchez Pérez, Raya Eilam, Eli Pikarsky, Luis Paz‐Ares, Yosef Yarden

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation <scp>EGFR</scp> inhibitors

    An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation <scp>EGFR</scp> inhibitors by Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick G. A. Burton, L. E. Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: